Skip to main content
. 2021 Feb 25;12:622601. doi: 10.3389/fimmu.2021.622601

Figure 2.

Figure 2

Potential therapeutic TGF-β modulating drugs and the immunosuppressive functions of TGF-β. The figure provides an overview over potential therapeutic approaches and the immunosuppressive effects of TGF-β. (A) Several drugs targeting TGF-β or its receptors are currently being tested in non-septic patients. Interestingly an anti- programmed cell death 1 ligand 1 (PD-L1)/TGF-β fusion protein is also being tested. The upregulation of PD-L1 is associated with monocyte dysfunction in post-traumatic and septic immune dysfunction (32). (B) TGF-β exerts immunosuppressive effects on both innate and adaptive immune cells. The figure contains adapted graphics from Les Laboratoirs Servier - Medical Art under the terms of the Creative Commons Attribution License (CC BY) for non-commercial use. The use, distribution or reproduction in other forums is permitted: https://creativecommons.org/licenses/by/3.0/legalcode, last accessed July 30th, 2020.